GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial ...

D. Boral Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $14 from $18 and keeps a Buy rating on the shares.

Peer-Reviewed Data Reinforces GeoVax's Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax to Present Clinical Data at Upcoming April Industry Events 15.04.2025 / 15:04 CET/CEST The issuer is solely responsible for the content of ...

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing vaccines with a current market capitalization of $19.78 million, announced today that its shareholders have ...

Q4 2024 Earnings Call Transcript March 27, 2025 GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.79. Operator: Good afternoon. And welcome everyone to the ...

GEOVAX LABS ($GOVX) is expected to release its quarterly earnings data on Thursday, March 27th after market close, per Finnhub. Analysts are expecting revenue of ...

Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd ...